Valtecne (VLT) Q1 2025 TU earnings summary

Executive summary

• Pro-forma Q1 2025 revenues reached €9.4 million after the acquisition of Utilità S.r.l., down 4.3% year-over-year.

• The medical business line now accounts for 75% of total revenues, reflecting strategic focus.

• Stand-alone Q1 2025 revenues were €7.9 million, a 6.0% decrease compared to Q1 2024.

Financial highlights

• Pro-forma medical segment revenues grew 4.6% year-over-year to €7.0 million.

• Pro-forma industrial segment revenues declined 23.9% to €2.3 million.

• Stand-alone medical revenues rose 7.9% to €6.0 million, while industrial fell 33.2% to €1.9 million.

• EBITDA Adjusted for FY 2024 was €7.5 million, with a margin of 25.1%.

Outlook and guidance

• Continued investment in the medical segment, especially orthopedics and dental, is expected due to market growth opportunities.

• Orthoworld forecasts a 4.3% annual growth for the orthopedic sector in 2025.